Steve Schonfeld’s Apexigen, Inc. Common Stock APGN Stock Holding History

Steve Schonfeld’s Portfolio APGN Stock Details APGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-28,809	Closed	-$293K	–	3285
2022 Q2	$293K	Buy	28,809 +3,679	+15%	+$37.2K	﹤0.01%	1690
2022 Q1	$253K	Buy	25,130 +2,245	+10%	+$22.5K	﹤0.01%	1790
2021 Q4	$229K	Buy	22,885 +7,317	+47%	+$72.9K	﹤0.01%	1661
2021 Q3	$155K	Buy	+15,568	New	+$154K	﹤0.01%	1837

Other funds holding APGN

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Yu Fan $108M AUM 137.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Steve Schonfeld's APGN Position: Q3 2022 in Review

Steve Schonfeld sold out of Apexigen, Inc. Common Stock (APGN) in Q3 2022, closing a stake of 28,809 shares — an estimated $293K sold.

Steve Schonfeld first reported a position in APGN in Q3 2021 and held it in 4 quarters. The position peaked at $293K in Q2 2022. 18 funds tracked by Wall St. Rank hold APGN as of Q3 2022.

Steve Schonfeld reported no remaining Apexigen, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Steve Schonfeld sold 28,809 Apexigen, Inc. Common Stock shares in Q3 2022, an estimated $293K.
Steve Schonfeld first reported a position in Apexigen, Inc. Common Stock in Q3 2021 and held it in 4 quarters.
Steve Schonfeld's Apexigen, Inc. Common Stock position peaked at $293K in Q2 2022.
18 funds tracked by Wall St. Rank held Apexigen, Inc. Common Stock as of Q3 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.